The emerging roles of human tissue kallikreins in cancer (original) (raw)

• Liotta, L. A. & Kohn, E. C. The microenvironment of the tumour–host interface. Nature 411, 375–379 (2001).
  Article CAS PubMed Google Scholar
• Puente, X. S., Sanchez, L. M., Overall, C. M. & Lopez-Otin, C. Human and mouse proteases: a comparative genomic approach. Nature Rev. Genet. 4, 544–558 (2003). The first study to compare the protease repertoire (degradome) within human and mouse genomes and to report that the KLK locus is the largest cluster of contiguous protease genes within the human genome.
  Article CAS PubMed Google Scholar
• Werb, Z. ECM and cell surface proteolysis: regulating cellular ecology. Cell 91, 439–442 (1997).
  Article CAS PubMed Google Scholar
• Hara, M., Koyanagi, Y., Inoue, T. & Fukuyama, T. [Some physico-chemical characteristics of “-seminoprotein”, an antigenic component specific for human seminal plasma. Forensic immunological study of body fluids and secretion. VII.] Nippon Hoigaku Zasshi 25, 322–324 (1971).
  CAS PubMed Google Scholar
• Riegman, P. H. et al. The prostate-specific antigen gene and the human glandular kallikrein-1 gene are tandemly located on chromosome 19. FEBS Lett. 247, 123–126 (1989).
  Article CAS PubMed Google Scholar
• Diamandis, E. P. et al. New nomenclature for the human tissue kallikrein gene family. Clin. Chem. 46, 1855–1858 (2000). This paper describes the current official nomenclature used to denote human kallikrein genes and proteins and the rationale behind its use.
  Article CAS PubMed Google Scholar
• Yousef, G. M., Chang, A., Scorilas, A. & Diamandis, E. P. Genomic organization of the human kallikrein gene family on chromosome 19q13.3-q13.4. Biochem. Biophys. Res. Commun. 276, 125–133 (2000). The first report to describe the topology and organization of the extended human kallikrein locus on 19q13.4; later confirmed by others (reference 8).
  Article CAS PubMed Google Scholar
• Harvey, T. J. et al. Tissue-specific expression patterns and fine mapping of the human kallikrein (KLK) locus on proximal 19q13.4. J. Biol. Chem. 275, 37397–37406 (2000).
  Article CAS PubMed Google Scholar
• Cleutjens, K. B., van Eekelen, C. C., van der Korput, H. A., Brinkmann, A. O. & Trapman, J. Two androgen response regions cooperate in steroid hormone regulated activity of the prostate-specific antigen promoter. J. Biol. Chem. 271, 6379–6388 (1996).
  Article CAS PubMed Google Scholar
• Smith, M. S., Lechago, J., Wines, D. R., MacDonald, R. J. & Hammer, R. E. Tissue-specific expression of kallikrein family transgenes in mice and rats. DNA Cell Biol. 11, 345–358 (1992).
  Article CAS PubMed Google Scholar
• Mikolajczyk, S. D. et al. Ala217 is important for the catalytic function and autoactivation of prostate-specific human kallikrein 2. Eur. J. Biochem. 246, 440–446 (1997).
  Article CAS PubMed Google Scholar
• Magklara, A. et al. Characterization of the enzymatic activity of human kallikrein 6: autoactivation, substrate specificity, and regulation by inhibitors. Biochem. Biophys. Res. Commun. 307, 948–955 (2003).
  Article CAS PubMed Google Scholar
• Sotiropoulou, G. et al. Emerging interest in the kallikrein gene family for understanding and diagnosing cancer. Oncol. Res. 13, 381–391 (2003).
  Article PubMed Google Scholar
• Lovgren, J., Rajakoski, K., Karp, M., Lundwall, A. & Lilja, H. Activation of the zymogen form of prostate-specific antigen by human glandular kallikrein 2. Biochem. Biophys. Res. Commun. 238, 549–555 (1997).
  Article CAS PubMed Google Scholar
• Takayama, T. K., McMullen, B. A., Nelson, P. S., Matsumura, M. & Fujikawa, K. Characterization of hK4 (prostase), a prostate-specific serine protease: activation of the precursor of prostate specific antigen (pro-PSA) and single-chain urokinase-type plasminogen activator and degradation of prostatic acid phosphatase. Biochemistry 40, 15341–15348 (2001).
  Article CAS PubMed Google Scholar
• Takayama, T. K., Carter, C. A. & Deng, T. Activation of prostate-specific antigen precursor (pro-PSA) by prostin, a novel human prostatic serine protease identified by degenerate PCR. Biochemistry 40, 1679–1687 (2001).
  Article CAS PubMed Google Scholar
• Caubet, C. et al. Degradation of corneodesmosome proteins by two serine proteases of the kallikrein family, SCTE/KLK5/hK5 and SCCE/KLK7/hK7. J. Invest Dermatol. 122, 1235–1244 (2004). The first report to demonstrate that an hK cascade might regulate skin desquamation.
  Article CAS PubMed Google Scholar
• Takayama, T. K., Fujikawa, K. & Davie, E. W. Characterization of the precursor of prostate-specific antigen. Activation by trypsin and by human glandular kallikrein. J. Biol. Chem. 272, 21582–21588 (1997).
  Article CAS PubMed Google Scholar
• Takada, Y., Skidgel, R. A. & Erdos, E. G. Purification of human urinary prokallikrein. Identification of the site of activation by the metalloproteinase thermolysin. Biochem. J. 232, 851–858 (1985).
  Article CAS PubMed PubMed Central Google Scholar
• Heeb, M. J. & Espana, F. α2-macroglobulin and C1-inactivator are plasma inhibitors of human glandular kallikrein. Blood Cells Mol. Dis. 24, 412–419 (1998).
  Article CAS PubMed Google Scholar
• Christensson, A., Laurell, C. B. & Lilja, H. Enzymatic activity of prostate-specific antigen and its reactions with extracellular serine proteinase inhibitors. Eur. J. Biochem. 194, 755–763 (1990).
  Article CAS PubMed Google Scholar
• Komatsu, N. et al. Expression and localization of tissue kallikrein mRNAs in human epidermis and appendages. J. Invest. Dermatol. 121, 542–549 (2003).
  Article CAS PubMed Google Scholar
• Rittenhouse, H. G., Finlay, J. A., Mikolajczyk, S. D. & Partin, A. W. Human Kallikrein 2 (hK2) and prostate-specific antigen (PSA): two closely related, but distinct, kallikreins in the prostate. Crit. Rev. Clin. Lab. Sci. 35, 275–368 (1998). An extensive review on hk2 and hK3/PSA that describes their discovery, isolation, biochemical characteristics and clinical applications.
  Article CAS PubMed Google Scholar
• Bayes, A. et al. Human kallikrein 6 activity is regulated via an autoproteolytic mechanism of activation/inactivation. Biol. Chem. 385, 517–524 (2004).
  Article CAS PubMed Google Scholar
• Hansson, L. et al. Cloning, expression, and characterization of stratum corneum chymotryptic enzyme. A skin-specific human serine proteinase. J. Biol. Chem. 269, 19420–19426 (1994).
  Article CAS PubMed Google Scholar
• Lovgren, J., Airas, K. & Lilja, H. Enzymatic action of human glandular kallikrein 2 (hK2). Substrate specificity and regulation by Zn2+ and extracellular protease inhibitors. Eur. J. Biochem. 262, 781–789 (1999).
  Article CAS PubMed Google Scholar
• Malm, J., Hellman, J., Hogg, P. & Lilja, H. Enzymatic action of prostate-specific antigen (PSA or hK3): substrate specificity and regulation by Zn2+, a tight-binding inhibitor. Prostate 45, 132–139 (2000).
  Article CAS PubMed Google Scholar
• Deperthes, D. Phage display substrate: a blind method for determining protease specificity. Biol. Chem. 383, 1107–1112 (2002). A comprehensive review describing the feasibility of using phage display for the identification of protease specificity and putative substrates.
  Article CAS PubMed Google Scholar
• Harris, J. L. et al. Rapid and general profiling of protease specificity by using combinatorial fluorogenic substrate libraries. Proc. Natl Acad. Sci. USA 97, 7754–7759 (2000). This paper describes the preparation and use of exhaustive fluorogenic tetrapeptide substrate libraries to identify the N-terminal substrate specificities of proteases.
  Article CAS PubMed PubMed Central Google Scholar
• Cloutier, S. M. et al. Substrate specificity of human kallikrein 2 (hK2) as determined by phage display technology. Eur. J. Biochem. 269, 2747–2754 (2002).
  Article CAS PubMed Google Scholar
• Coombs, G. S. et al. Substrate specificity of prostate-specific antigen (PSA). Chem. Biol. 5, 475–488 (1998).
  Article CAS PubMed Google Scholar
• Obiezu, C. V. et al. Higher human kallikrein gene 4 (klk4) expression indicates poor prognosis of ovarian cancer patients. Clin. Cancer Res. 7, 2380–2386 (2001).
  CAS PubMed Google Scholar
• Dong, Y. et al. Human kallikrein 4 (KLK4) is highly expressed in serous ovarian carcinomas. Clin. Cancer Res. 7, 2363–2371 (2001).
  CAS PubMed Google Scholar
• Kim, H. et al. Human kallikrein gene 5 (KLK5) expression is an indicator of poor prognosis in ovarian cancer. Br. J. Cancer 84, 643–650 (2001).
  Article CAS PubMed PubMed Central Google Scholar
• Yousef, G. M. et al. Human kallikrein 5: a potential novel serum biomarker for breast and ovarian cancer. Cancer Res. 63, 3958–3965 (2003).
  CAS PubMed Google Scholar
• Anisowicz, A., Sotiropoulou, G., Stenman, G., Mok, S. C. & Sager, R. A novel protease homolog differentially expressed in breast and ovarian cancer. Mol. Med. 2, 624–636 (1996).
  Article CAS PubMed PubMed Central Google Scholar
• Tanimoto, H., Underwood, L. J., Shigemasa, K., Parmley, T. H. & O'Brien, T. J. Increased expression of protease M in ovarian tumors. Tumour Biol. 22, 11–18 (2001).
  Article CAS PubMed Google Scholar
• Diamandis, E. P., Yousef, G. M., Soosaipillai, A. R. & Bunting, P. Human kallikrein 6 (zyme/protease M/neurosin): a new serum biomarker of ovarian carcinoma. Clin. Biochem. 33, 579–583 (2000). This study was among the first to show that a member of the extended kallikrein family might be a promising cancer biomarker.
  Article CAS PubMed Google Scholar
• Tanimoto, H. et al. The stratum corneum chymotryptic enzyme that mediates shedding and desquamation of skin cells is highly overexpressed in ovarian tumor cells. Cancer 86, 2074–2082 (1999).
  Article CAS PubMed Google Scholar
• Underwood, L. J. et al. Cloning of tumor-associated differentially expressed gene-14, a novel serine protease overexpressed by ovarian carcinoma. Cancer Res. 59, 4435–4439 (1999).
  CAS PubMed Google Scholar
• Magklara, A. et al. The human KLK8 (neuropsin/ovasin) gene: identification of two novel splice variants and its prognostic value in ovarian cancer. Clin. Cancer Res. 7, 806–811 (2001).
  CAS PubMed Google Scholar
• Kishi, T. et al. Human kallikrein 8, a novel biomarker for ovarian carcinoma. Cancer Res. 63, 2771–2774 (2003).
  CAS PubMed Google Scholar
• Luo, L. Y. et al. Prognostic value of human kallikrein 10 expression in epithelial ovarian carcinoma. Clin. Cancer Res. 7, 2372–2379 (2001).
  CAS PubMed Google Scholar
• Luo, L., Bunting, P., Scorilas, A. & Diamandis, E. P. Human kallikrein 10: a novel tumor marker for ovarian carcinoma? Clin. Chim. Acta 306, 111–118 (2001).
  Article CAS PubMed Google Scholar
• Luo, L. Y. et al. The serum concentration of human kallikrein 10 represents a novel biomarker for ovarian cancer diagnosis and prognosis. Cancer Res. 63, 807–811 (2003).
  CAS PubMed Google Scholar
• Diamandis, E. P. et al. Human kallikrein 11: a new biomarker of prostate and ovarian carcinoma. Cancer Res. 62, 295–300 (2002).
  CAS PubMed Google Scholar
• Kapadia, C. et al. Human kallikrein 13: production and purification of recombinant protein and monoclonal and polyclonal antibodies, and development of a sensitive and specific immunofluorometric assay. Clin. Chem. 49, 77–86 (2003).
  Article CAS PubMed Google Scholar
• Borgono, C. A. et al. Human kallikrein 14: a new potential biomarker for ovarian and breast cancer. Cancer Res. 63, 9032–9041 (2003).
  CAS PubMed Google Scholar
• Yousef, G. M. et al. Prognostic value of the human kallikrein gene 15 expression in ovarian cancer. J. Clin. Oncol. 21, 3119–3126 (2003).
  Article CAS PubMed Google Scholar
• Yousef, G. M. et al. Parallel overexpression of seven kallikrein genes in ovarian cancer. Cancer Res. 63, 2223–2227 (2003).
  CAS PubMed Google Scholar
• Welsh, J. B. et al. Large-scale delineation of secreted protein biomarkers overexpressed in cancer tissue and serum. Proc. Natl Acad. Sci. USA 100, 3410–3415 (2003).
  Article CAS PubMed PubMed Central Google Scholar
• Adib, T. R. et al. Predicting biomarkers for ovarian cancer using gene-expression microarrays. Br. J. Cancer 90, 686–692 (2004).
  Article CAS PubMed PubMed Central Google Scholar
• Yu, H. et al. Prostate specific antigen in breast cancer, benign breast disease and normal breast tissue. Breast Cancer Res. Treat. 40, 171–178 (1996).
  Article CAS PubMed Google Scholar
• Yu, H., Levesque, M. A., Clark, G. M. & Diamandis, E. P. Prognostic value of prostate-specific antigen for women with breast cancer: a large United States cohort study. Clin. Cancer Res. 4, 1489–1497 (1998).
  CAS PubMed Google Scholar
• Liu, X. L., Wazer, D. E., Watanabe, K. & Band, V. Identification of a novel serine protease-like gene, the expression of which is down-regulated during breast cancer progression. Cancer Res. 56, 3371–3379 (1996).
  CAS PubMed Google Scholar
• Goyal, J. et al. The role for NES1 serine protease as a novel tumor suppressor. Cancer Res. 58, 4782–4786 (1998).
  CAS PubMed Google Scholar
• Dhar, S. et al. Analysis of normal epithelial cell specific-1 (NES1)/Kallikrein 10 mRNA expression by in situ hybridization, a novel marker for breast cancer. Clin. Cancer Res. 7, 3393–3398 (2001).
  CAS PubMed Google Scholar
• Yousef, G. M., Magklara, A. & Diamandis, E. P. KLK12 is a novel serine protease and a new member of the human kallikrein gene family-differential expression in breast cancer. Genomics 69, 331–341 (2000).
  Article CAS PubMed Google Scholar
• Yousef, G. M., Chang, A. & Diamandis, E. P. Identification and characterization of KLK-L4, a new kallikrein-like gene that appears to be down-regulated in breast cancer tissues. J. Biol. Chem. 275, 11891–11898 (2000).
  Article CAS PubMed Google Scholar
• Yousef, G. M. et al. Cloning of a new member of the human kallikrein gene family, KLK14, which is down-regulated in different malignancies. Cancer Res. 61, 3425–3431 (2001).
  CAS PubMed Google Scholar
• Yousef, G. M. et al. Kallikrein gene downregulation in breast cancer. Br. J. Cancer 90, 167–172 (2004).
  Article CAS PubMed PubMed Central Google Scholar
• Magklara, A. et al. Decreased concentrations of prostate-specific antigen and human glandular kallikrein 2 in malignant versus nonmalignant prostatic tissue. Urology 56, 527–532 (2000).
  Article CAS PubMed Google Scholar
• Abrahamsson, P. A., Lilja, H., Falkmer, S. & Wadstrom, L. B. Immunohistochemical distribution of the three predominant secretory proteins in the parenchyma of hyperplastic and neoplastic prostate glands. Prostate 12, 39–46 (1988).
  Article CAS PubMed Google Scholar
• Pretlow, T. G. et al. Tissue concentrations of prostate-specific antigen in prostatic carcinoma and benign prostatic hyperplasia. Int. J. Cancer 49, 645–649 (1991).
  Article CAS PubMed Google Scholar
• Hakalahti, L. et al. Evaluation of PAP and PSA gene expression in prostatic hyperplasia and prostatic carcinoma using northern-blot analyses, in situ hybridization and immunohistochemical stainings with monoclonal and bispecific antibodies. Int. J. Cancer 55, 590–597 (1993).
  Article CAS PubMed Google Scholar
• Yousef, G. M. et al. Down-regulation of the human kallikrein gene 5 (KLK5) in prostate cancer tissues. Prostate 51, 126–132 (2002).
  Article CAS PubMed Google Scholar
• Luo, L. Y. & Diamandis, E. P. Down-regulation of the normal epithelial cell–specific 1 (NES1) gene is associated with unfavorable outcome of prostate cancer. Clin. Biochem. 33, 237 (2000).
  Article Google Scholar
• Petraki, C. D. et al. Immunohistochemical localization of human kallikreins 6, 10 and 13 in benign and malignant prostatic tissues. Prostate Cancer Prostatic Dis. 6, 223–227 (2003).
  Article CAS PubMed Google Scholar
• Yousef, G. M. et al. Differential expression of Kallikrein gene 5 in cancerous and normal testicular tissues. Urology 60, 714–718 (2002).
  Article PubMed Google Scholar
• Luo, L. Y., Rajpert-De Meyts, E. R., Jung, K. & Diamandis, E. P. Expression of the normal epithelial cell-specific 1 (NES1; KLK10) candidate tumour suppressor gene in normal and malignant testicular tissue. Br. J. Cancer 85, 220–224 (2001).
  Article CAS PubMed PubMed Central Google Scholar
• Bhattacharjee, A. et al. Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc. Natl Acad. Sci. USA 98, 13790–13795 (2001).
  Article CAS PubMed PubMed Central Google Scholar
• Iacobuzio-Donahue, C. A. et al. Highly expressed genes in pancreatic ductal adenocarcinomas: a comprehensive characterization and comparison of the transcription profiles obtained from three major technologies. Cancer Res. 63, 8614–8622 (2003).
  CAS PubMed Google Scholar
• Yousef, G. M. et al. In-silico analysis of kallikrein gene expression in pancreatic and colon cancers. AntiCancer Res. 24, 43–51 (2004).
  CAS PubMed Google Scholar
• Chung, C. H. et al. Molecular classification of head and neck squamous cell carcinomas using patterns of gene expression. Cancer Cell 5, 489–500 (2004).
  Article CAS PubMed Google Scholar
• Roman-Gomez, J. et al. The normal epithelial cell-specific 1 (NES1) gene, a candidate tumor suppressor gene on chromosome 19q13.3-4, is downregulated by hypermethylation in acute lymphoblastic leukemia. Leukemia 18, 362–365 (2004).
  Article CAS PubMed Google Scholar
• Denmeade, S. R., Sokoll, L. J., Chan, D. W., Khan, S. R. & Isaacs, J. T. Concentration of enzymatically active prostate-specific antigen (PSA) in the extracellular fluid of primary human prostate cancers and human prostate cancer xenograft models. Prostate 48, 1–6 (2001).
  Article CAS PubMed Google Scholar
• Rajah, R., Valentinis, B. & Cohen, P. Insulin-like growth factor (IGF)-binding protein-3 induces apoptosis and mediates the effects of transforming growth factor-β1 on programmed cell death through a p53- and IGF-independent mechanism. J. Biol. Chem. 272, 12181–12188 (1997).
  Article CAS PubMed Google Scholar
• Cohen, P. et al. Prostate-specific antigen (PSA) is an insulin-like growth factor binding protein-3 protease found in seminal plasma. J. Clin. Endocrinol. Metab. 75, 1046–1053 (1992). One of the first reports to show that kallikreins might be involved in tumour progression by modulating tumour-cell growth in vitro and in vivo through growth factors.
  CAS PubMed Google Scholar
• Rehault, S. et al. Insulin-like growth factor binding proteins (IGFBPs) as potential physiological substrates for human kallikreins hK2 and hK3. Eur. J. Biochem. 268, 2960–2968 (2001).
  Article CAS PubMed Google Scholar
• Sutkowski, D. M. et al. Growth regulation of prostatic stromal cells by prostate-specific antigen. J. Natl Cancer Inst. 91, 1663–1669 (1999).
  Article CAS PubMed Google Scholar
• Sun, X. Y., Donald, S. P. & Phang, J. M. Testosterone and prostate specific antigen stimulate generation of reactive oxygen species in prostate cancer cells. Carcinogenesis 22, 1775–1780 (2001).
  Article CAS PubMed Google Scholar
• Frenette, G., Tremblay, R. R., Lazure, C. & Dube, J. Y. Prostatic kallikrein hK2, but not prostate-specific antigen (hK3), activates single-chain urokinase-type plasminogen activator. Int. J. Cancer 71, 897–899 (1997).
  Article CAS PubMed Google Scholar
• Mikolajczyk, S. D., Millar, L. S., Kumar, A. & Saedi, M. S. Prostatic human kallikrein 2 inactivates and complexes with plasminogen activator inhibitor-1. Int. J. Cancer 81, 438–442 (1999).
  Article CAS PubMed Google Scholar
• D'Andrea, M. R., Derian, C. K., Santulli, R. J. & Andrade-Gordon, P. Differential expression of protease-activated receptors-1 and-2 in stromal fibroblasts of normal, benign, and malignant human tissues. Am. J. Pathol. 158, 2031–2041 (2001).
  Article CAS PubMed PubMed Central Google Scholar
• Ohta, T. et al. Protease-activated receptor-2 expression and the role of trypsin in cell proliferation in human pancreatic cancers. Int. J. Oncol. 23, 61–66 (2003).
  CAS PubMed Google Scholar
• Lai, L. C., Erbas, H., Lennard, T. W. & Peaston, R. T. Prostate-specific antigen in breast cyst fluid: possible role of prostate-specific antigen in hormone-dependent breast cancer. Int. J. Cancer 66, 743–746 (1996).
  Article CAS PubMed Google Scholar
• Yu, H. et al. Prostate-specific antigen is a new favorable prognostic indicator for women with breast cancer. Cancer Res. 55, 2104–2110 (1995).
  CAS PubMed Google Scholar
• Derynck, R., Akhurst, R. J. & Balmain, A. TGF-β signaling in tumor suppression and cancer progression. Nature Genet. 29, 117–129 (2001).
  Article CAS PubMed Google Scholar
• Fortier, A. H., Nelson, B. J., Grella, D. K. & Holaday, J. W. Antiangiogenic activity of prostate-specific antigen. J. Natl Cancer Inst. 91, 1635–1640 (1999). The first paper to illustrate that a kallikrein family member might be involved in the regulation of angiogenesis in vivo.
  Article CAS PubMed Google Scholar
• Denmeade, S. R., Litvinov, I., Sokoll, L. J., Lilja, H. & Isaacs, J. T. Prostate-specific antigen (PSA) protein does not affect growth of prostate cancer cells in vitro or prostate cancer xenografts in vivo. Prostate 56, 45–53 (2003).
  Article CAS PubMed Google Scholar
• Hanahan, D. & Folkman, J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86, 353–364 (1996).
  Article CAS PubMed Google Scholar
• Deperthes, D. et al. Potential involvement of kallikrein hK2 in the hydrolysis of the human seminal vesicle proteins after ejaculation. J. Androl. 17, 659–665 (1996).
  CAS PubMed Google Scholar
• Lilja, H. A kallikrein-like serine protease in prostatic fluid cleaves the predominant seminal vesicle protein. J. Clin. Invest. 76, 1899–1903 (1985).
  Article CAS PubMed PubMed Central Google Scholar
• Watt, K. W., Lee, P. J., M'Timkulu, T., Chan, W. P. & Loor, R. Human prostate-specific antigen: structural and functional similarity with serine proteases. Proc. Natl Acad. Sci. USA 83, 3166–3170 (1986).
  Article CAS PubMed PubMed Central Google Scholar
• Webber, M. M., Waghray, A. & Bello, D. Prostate-specific antigen, a serine protease, facilitates human prostate cancer cell invasion. Clin. Cancer Res. 1, 1089–1094 (1995).
  CAS PubMed Google Scholar
• Bernett, M. J. et al. Crystal structure and biochemical characterization of human kallikrein 6 reveals that a trypsin-like kallikrein is expressed in the central nervous system. J. Biol. Chem. 277, 24562–24570 (2002). Together with references 147 and 148, this paper describes the three-dimensional trypsin-like fold of human kallikreins as determined by X-ray cystallography.
  Article CAS PubMed Google Scholar
• Barrett, A. D., Rawlings, N. D. & Woessner, J. F. (eds) Handbook of Proteolytic Enzymes. 1556–1558 (Elsevier Academic, London, 2004). A comprehensive textbook that categorizes and describes all known proteases.
  Google Scholar
• Tschesche, H., Michaelis, J., Kohnert, U., Fedrowitz, J. & Oberhoff, R. Tissue kallikrein effectively activates latent matrix degrading metalloenzymes. Adv. Exp. Med. Biol. 247A, 545–548 (1989).
  Article CAS PubMed Google Scholar
• Desrivieres, S. et al. Activation of the 92 kDa type IV collagenase by tissue kallikrein. J. Cell Physiol. 157, 587–593 (1993).
  Article CAS PubMed Google Scholar
• Menashi, S. et al. Regulation of 92-kDa gelatinase B activity in the extracellular matrix by tissue kallikrein. Ann. NY Acad. Sci. 732, 466–468 (1994).
  Article CAS PubMed Google Scholar
• Killian, C. S., Corral, D. A., Kawinski, E. & Constantine, R. I. Mitogenic response of osteoblast cells to prostate-specific antigen suggests an activation of latent TGF-β and a proteolytic modulation of cell adhesion receptors. Biochem. Biophys. Res. Commun. 192, 940–947 (1993).
  Article CAS PubMed Google Scholar
• Plendl, J. et al. Expression of tissue kallikrein and kinin receptors in angiogenic microvascular endothelial cells. Biol. Chem. 381, 1103–1115 (2000).
  Article CAS PubMed Google Scholar
• Emanueli, C. et al. Local delivery of human tissue kallikrein gene accelerates spontaneous angiogenesis in mouse model of hindlimb ischemia. Circulation 103, 125–132 (2001).
  Article CAS PubMed Google Scholar
• Jin, E. et al. Protease-activated receptor (PAR)-1 and PAR-2 participate in the cell growth of alveolar capillary endothelium in primary lung adenocarcinomas. Cancer 97, 703–713 (2003).
  Article CAS PubMed Google Scholar
• Heidtmann, H. H. et al. Generation of angiostatin-like fragments from plasminogen by prostate-specific antigen. Br. J. Cancer 81, 1269–1273 (1999).
  Article CAS PubMed PubMed Central Google Scholar
• Fortier, A. H. et al. Recombinant prostate specific antigen inhibits angiogenesis in vitro and in vivo. Prostate 56, 212–219 (2003).
  Article CAS PubMed Google Scholar
• Papadopoulos, I., Sivridis, E., Giatromanolaki, A. & Koukourakis, M. I. Tumor angiogenesis is associated with MUC1 overexpression and loss of prostate-specific antigen expression in prostate cancer. Clin. Cancer Res. 7, 1533–1538 (2001).
  CAS PubMed Google Scholar
• Hoffman, J. A. et al. Progressive vascular changes in a transgenic mouse model of squamous cell carcinoma. Cancer Cell 4, 383–391 (2003).
  Article CAS PubMed Google Scholar
• Wolf, W. C., Evans, D. M., Chao, L. & Chao, J. A synthetic tissue kallikrein inhibitor suppresses cancer cell invasiveness. Am. J. Pathol. 159, 1797–1805 (2001).
  Article CAS PubMed PubMed Central Google Scholar
• Ishii, K. et al. Evidence that the prostate-specific antigen (PSA)/Zn2+ axis may play a role in human prostate cancer cell invasion. Cancer Lett. 207, 79–87 (2004).
  Article CAS PubMed Google Scholar
• Henrikson, K. P., Salazar, S. L., Fenton, J. W. & Pentecost, B. T. Role of thrombin receptor in breast cancer invasiveness. Br. J. Cancer 79, 401–406 (1999).
  Article CAS PubMed PubMed Central Google Scholar
• Kamath, L., Meydani, A., Foss, F. & Kuliopulos, A. Signaling from protease-activated receptor-1 inhibits migration and invasion of breast cancer cells. Cancer Res. 61, 5933–5940 (2001).
  CAS PubMed Google Scholar
• Romanov, V. I., Whyard, T., Adler, H. L., Waltzer, W. C. & Zucker, S. Prostate cancer cell adhesion to bone marrow endothelium: the role of prostate-specific antigen. Cancer Res. 64, 2083–2089 (2004).
  Article CAS PubMed Google Scholar
• Yonou, H. et al. Prostate-specific antigen induces osteoplastic changes by an autonomous mechanism. Biochem. Biophys. Res. Commun. 289, 1082–1087 (2001).
  Article CAS PubMed Google Scholar
• Iwamura, M., Hellman, J., Cockett, A. T., Lilja, H. & Gershagen, S. Alteration of the hormonal bioactivity of parathyroid hormone-related protein (PTHrP) as a result of limited proteolysis by prostate-specific antigen. Urology 48, 317–325 (1996).
  Article CAS PubMed Google Scholar
• Cramer, S. D., Chen, Z. & Peehl, D. M. Prostate specific antigen cleaves parathyroid hormone-related protein in the PTH-like domain: inactivation of PTHrP-stimulated cAMP accumulation in mouse osteoblasts. J. Urol. 156, 526–531 (1996).
  Article CAS PubMed Google Scholar
• Ni, X. et al. Characterisation of human kallikrein 6/protease M expression in ovarian cancer. Br. J. Cancer 91, 725–731 (2004).
  Article CAS PubMed PubMed Central Google Scholar
• Majumdar, S. & Diamandis, E. P. The promoter and the enhancer region of the KLK 3 (prostate specific antigen) gene is frequently mutated in breast tumours and in breast carcinoma cell lines. Br. J. Cancer 79, 1594–1602 (1999).
  Article CAS PubMed PubMed Central Google Scholar
• Tsuyuki, D., Grass, L. & Diamandis, E. P. Frequent detection of mutations in the 5′ flanking region of the prostate-specific antigen gene in female breast cancer. Eur. J. Cancer 33, 1851–1854 (1997).
  Article CAS PubMed Google Scholar
• Bharaj, B. et al. Breast cancer prognostic significance of a single nucleotide polymorphism in the proximal androgen response element of the prostate specific antigen gene promoter. Breast Cancer Res. Treat. 61, 111–119 (2000).
  Article CAS PubMed Google Scholar
• Xue, W. et al. Susceptibility to prostate cancer: interaction between genotypes at the androgen receptor and prostate-specific antigen loci. Cancer Res. 60, 839–841 (2000).
  CAS PubMed Google Scholar
• Chiang, C. H., Chen, K. K., Chang, L. S. & Hong, C. J. The impact of polymorphism on prostate specific antigen gene on the risk, tumor volume and pathological stage of prostate cancer. J. Urol. 171, 1529–1532 (2004).
  Article CAS PubMed Google Scholar
• Wang, L. Z. et al. Polymorphisms in prostate-specific antigen (PSA) gene, risk of prostate cancer, and serum PSA levels in Japanese population. Cancer Lett. 202, 53–59 (2003).
  Article CAS PubMed Google Scholar
• Cramer, S. D. et al. Association between genetic polymorphisms in the prostate-specific antigen gene promoter and serum prostate-specific antigen levels. J. Natl. Cancer Inst. 95, 1044–1053 (2003).
  Article CAS PubMed Google Scholar
• Bharaj, B. B., Luo, L. Y., Jung, K., Stephan, C. & Diamandis, E. P. Identification of single nucleotide polymorphisms in the human kallikrein 10 (KLK10) gene and their association with prostate, breast, testicular, and ovarian cancers. Prostate 51, 35–41 (2002).
  Article CAS PubMed Google Scholar
• Li, B. et al. CpG methylation as a basis for breast tumor-specific loss of NES1/kallikrein 10 expression. Cancer Res. 61, 8014–8021 (2001). The first study to propose an epigenetic mechanism for dysregulated kallikrein expression during tumorigenesis.
  CAS PubMed Google Scholar
• Magklara, A., Brown, T. J. & Diamandis, E. P. Characterization of androgen receptor and nuclear receptor co-regulator expression in human breast cancer cell lines exhibiting differential regulation of kallikreins 2 and 3. Int. J. Cancer 100, 507–514 (2002).
  Article CAS PubMed Google Scholar
• Stamey, T. A. et al. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N. Engl. J. Med. 317, 909–916 (1987).
  Article CAS PubMed Google Scholar
• Stenman, U. H. New ultrasensitive assays facilitate studies on the role of human glandular kallikrein (hK2) as a marker for prostatic disease. Clin. Chem. 45, 753–754 (1999).
  Article CAS PubMed Google Scholar
• Nakamura, T. et al. The usefulness of serum human kallikrein 11 for discriminating between prostate cancer and benign prostatic hyperplasia. Cancer Res. 63, 6543–6546 (2003).
  CAS PubMed Google Scholar
• Diamandis, E. P. et al. Human kallikrein 6 (hK6): a new potential serum biomarker for diagnosis and prognosis of ovarian carcinoma. J. Clin. Oncol. 21, 1035–1043 (2003).
  Article CAS PubMed Google Scholar
• Cloutier, S. M. et al. Development of recombinant inhibitors specific to human kallikrein 2 using phage-display selected substrates. Eur. J. Biochem. 271, 607–613 (2004). This paper describes a novel approach for designing kallikrein-specific inhibitors, which might be useful in anticancer therapies.
  Article CAS PubMed Google Scholar
• Denmeade, S. R. et al. Specific and efficient peptide substrates for assaying the proteolytic activity of prostate-specific antigen. Cancer Res. 57, 4924–4930 (1997).
  CAS PubMed PubMed Central Google Scholar
• Denmeade, S. R. et al. Enzymatic activation of a doxorubicin-peptide prodrug by prostate-specific antigen. Cancer Res. 58, 2537–2540 (1998).
  CAS PubMed Google Scholar
• DiPaola, R. S. et al. Characterization of a novel prostate-specific antigen-activated peptide-doxorubicin conjugate in patients with prostate cancer. J. Clin. Oncol. 20, 1874–1879 (2002).
  Article CAS PubMed Google Scholar
• DeFeo-Jones, D. et al. A prostate-specific antigen (PSA)-activated vinblastine prodrug selectively kills PSA-secreting cells in vivo. Mol. Cancer Ther. 1, 451–459 (2002).
  CAS PubMed Google Scholar
• Denmeade, S. R. et al. Prostate-specific antigen-activated thapsigargin prodrug as targeted therapy for prostate cancer. J. Natl. Cancer Inst. 95, 990–1000 (2003).
  Article CAS PubMed Google Scholar
• Latham, J. P., Searle, P. F., Mautner, V. & James, N. D. Prostate-specific antigen promoter/enhancer driven gene therapy for prostate cancer: construction and testing of a tissue-specific adenovirus vector. Cancer Res. 60, 334–341 (2000).
  CAS PubMed Google Scholar
• Suzuki, S. et al. Liposome-mediated gene therapy using HSV-TK/ganciclovir under the control of human PSA promoter in prostate cancer cells. Urol. Int. 67, 216–223 (2001).
  Article CAS PubMed Google Scholar
• Eder, J. P. et al. A phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer. Clin. Cancer Res. 6, 1632–1638 (2000).
  CAS PubMed Google Scholar
• Heiser, A. et al. Human dendritic cells transfected with renal tumor RNA stimulate polyclonal T-cell responses against antigens expressed by primary and metastatic tumors. Cancer Res. 61, 3388–3393 (2001).
  CAS PubMed Google Scholar
• Barrou, B. et al. Vaccination of prostatectomized prostate cancer patients in biochemical relapse, with autologous dendritic cells pulsed with recombinant human PSA. Cancer Immunol. Immunother. 53, 453–460 (2004).
  Article PubMed Google Scholar
• Diamandis, E. P., Yousef, G. M., Luo, L. Y., Magklara, A. & Obiezu, C. V. The new human kallikrein gene family: implications in carcinogenesis. Trends Endocrinol. Metab. 11, 54–60 (2000).
  Article CAS PubMed Google Scholar
• Yousef, G. M. & Diamandis, E. P. The new human tissue kallikrein gene family: structure, function, and association to disease. Endocr. Rev. 22, 184–204 (2001). A comprehensive review on the genomic characteristics and clinical usefulness of the extended human kallikrein family.
  CAS PubMed Google Scholar
• Clements, J. A., Willemsen, N. M., Myers, S. A. & Dong, Y. The tissue kallikrein family of serine proteases: functional roles in human disease and potential as clinical biomarkers. Crit. Rev. Clin. Lab. Sci. 41, 265–312 (2004).
  Article CAS PubMed Google Scholar
• Henttu, P. & Vihko, P. cDNA coding for the entire human prostate specific antigen shows high homologies to the human tissue kallikrein genes. Biochem. Biophys. Res. Commun. 160, 903–910 (1989).
  Article CAS PubMed Google Scholar
• Katz, B. A., Liu, B., Barnes, M. & Springman, E. B. Crystal structure of recombinant human tissue kallikrein at 2.0 A resolution. Protein Sci. 7, 875–885 (1998).
  Article CAS PubMed PubMed Central Google Scholar
• Gomis-Ruth, F. X. et al. The structure of human prokallikrein 6 reveals a novel activation mechanism for the kallikrein family. J. Biol. Chem. 277, 27273–27281 (2002).
  Article CAS PubMed Google Scholar
• Schechter, I. & Berger, A. On the size of the active site in proteases. I. Papain. Biochem. Biophys. Res. Commun. 27, 157–162 (1967).
  Article CAS PubMed Google Scholar
• Brillard-Bourdet, M., Moreau, T. & Gauthier, F. Substrate specificity of tissue kallikreins: importance of an extended interaction site. Biochim. Biophys. Acta 1246, 47–52 (1995).
  Article PubMed Google Scholar
• Oka, T. et al. Role of loop structures of neuropsin in the activity of serine protease and regulated secretion. J. Biol. Chem. 277, 14724–14730 (2002).
  Article CAS PubMed Google Scholar
• Modrek, B. & Lee, C. A genomic view of alternative splicing. Nature Genet. 30, 13–19 (2002).
  Article CAS PubMed Google Scholar
• Johnson, J. M. et al. Genome-wide survey of human alternative pre-mRNA splicing with exon junction microarrays. Science 302, 2141–2144 (2003). One of the latest studies to investigate the frequency of alternative pre-mRNA splicing within the human genome.
  Article CAS PubMed Google Scholar
• Xi, Z. et al. Kallikrein 4 is a predominantly nuclear protein and is overexpressed in prostate cancer. Cancer Res. 64, 2365–2370 (2004).
  Article CAS PubMed Google Scholar
• Dong, Y., Kaushal, A., Brattsand, M., Nicklin, J. & Clements, J. A. Differential Splicing of KLK5 and KLK7 in epithelial ovarian cancer produces novel variants with potential as cancer biomarkers. Clin. Cancer Res. 9, 1710–1720 (2003).
  CAS PubMed Google Scholar
• Kurlender, L. et al. Differential expression of a human kallikrein 5 (KLK5) splice variant in ovarian and prostate cancer. Tumor Biol. 25, 149–156 (2004).
  Article CAS Google Scholar
• Yousef, G. M. et al. The kallikrein gene 5 (KLK5) splice variant 2 is a new biomarker for breast and ovarian cancer. Tumor Biol. (in the press).
• Mitsui, S. et al. A novel isoform of a kallikrein-like protease, TLSP/hippostasin, (PRSS20), is expressed in the human brain and prostate. Biochem. Biophys. Res. Commun. 272, 205–211 (2000).
  Article CAS PubMed Google Scholar
• Nakamura, T. et al. Quantitative analysis of hippostasin/KLK11 gene expression in cancerous and noncancerous prostatic tissues. Urology 61, 1042–1046 (2003).
  Article PubMed Google Scholar
• Chang, A., Yousef, G. M., Jung, K., Meyts, E. R. & Diamanids, E. P. Identification and molecular characterization of five novel kallikrein gene 13 (KLK13;KLK-L4) splice variants: differential expression in human testis and testicular cancer. AntiCancer Res. 21, 3147–3152 (2001).
  CAS PubMed Google Scholar
• Kumar, A., Mikolajczyk, S. D., Goel, A. S., Millar, L. S. & Saedi, M. S. Expression of pro form of prostate-specific antigen by mammalian cells and its conversion to mature, active form by human kallikrein 2. Cancer Res. 57, 3111–3114 (1997).
  CAS PubMed Google Scholar
• Rehbock, J., Buchinger, P., Hermann, A. & Figueroa, C. Identification of immunoreactive tissue kallikrein in human ductal breast carcinomas. J. Cancer Res. Clin. Oncol. 121, 64–68 (1995).
  Article CAS PubMed Google Scholar
• Hermann, A., Buchinger, P. & Rehbock, J. Visualization of tissue kallikrein in human breast carcinoma by two-dimensional western blotting and immunohistochemistry. Biol. Chem. Hoppe Seyler 376, 365–370 (1995).
  Article CAS PubMed Google Scholar
• Howarth, D. J., Aronson, I. B. & Diamandis, E. P. Immunohistochemical localization of prostate-specific antigen in benign and malignant breast tissues. Br. J. Cancer 75, 1646–1651 (1997).
  Article CAS PubMed PubMed Central Google Scholar
• Yu, H. & Diamandis, E. P. Measurement of serum prostate specific antigen levels in women and in prostatectomized men with an ultrasensitive immunoassay technique. J. Urol. 153, 1004–1008 (1995).
  Article CAS PubMed Google Scholar
• Foekens, J. A. et al. Expression of prostate-specific antigen (PSA) correlates with poor response to tamoxifen therapy in recurrent breast cancer. Br. J. Cancer 79, 888–894 (1999).
  Article CAS PubMed PubMed Central Google Scholar
• Yousef, G. M. et al. Human kallikrein gene 5 (KLK5) expression by quantitative PCR: an independent indicator of poor prognosis in breast cancer. Clin. Chem. 48, 1241–1250 (2002).
  Article CAS PubMed Google Scholar
• Talieri, M., Diamandis, E. P., Gourgiotis, D., Mathioudaki, K. & Scorilas, A. Expression analysis of the human kallikrein 7 (KLK7) in breast tumors: a new potential biomarker for prognosis of breast carcinoma. Thromb. Haemost. 91, 180–186 (2004).
  Article CAS PubMed Google Scholar
• Yousef, G. et al. The prognostic value of the human kallikrein gene 9 (KLK9) in breast cancer. Breast Cancer Res. Treat. 78, 149–158 (2003).
  Article CAS PubMed Google Scholar
• Luo, L. Y., Diamandis, E. P., Look, M. P., Soosaipillai, A. P. & Foekens, J. A. Higher expression of human kallikrein 10 in breast cancer tissue predicts tamoxifen resistance. Br. J. Cancer 86, 1790–1796 (2002).
  Article CAS PubMed PubMed Central Google Scholar
• Chang, A. et al. Human kallikrein gene 13 (KLK13) expression by quantitative RT-PCR: an independent indicator of favourable prognosis in breast cancer. Br. J. Cancer 86, 1457–1464 (2002).
  Article CAS PubMed PubMed Central Google Scholar
• Yousef, G. M. et al. Quantitative analysis of human kallikrein gene 14 expression in breast tumours indicates association with poor prognosis. Br. J. Cancer 87, 1287–1293 (2002).
  Article CAS PubMed PubMed Central Google Scholar
• Yousef, G. M. et al. The androgen-regulated gene human kallikrein 15 (KLK15) is an independent and favourable prognostic marker for breast cancer. Br. J. Cancer 87, 1294–1300 (2002).
  Article CAS PubMed PubMed Central Google Scholar
• Cane, S. et al. The novel serine protease tumor-associated differentially expressed gene-14 (KLK8/Neuropsin/Ovasin) is highly overexpressed in cervical cancer. Am. J. Obstet. Gynecol. 190, 60–66 (2004).
  Article CAS PubMed Google Scholar
• Hibbs, K. et al. Differential gene expression in ovarian carcinoma: identification of potential biomarkers. Am. J. Pathol. 165, 397–414 (2004).
  Article CAS PubMed PubMed Central Google Scholar
• Diamandis, E. P. et al. Immunofluorometric quantification of human kallikrein 5 expression in ovarian cancer cytosols and its association with unfavorable patient prognosis. Tumour. Biol. 24, 299–309 (2003).
  Article CAS PubMed Google Scholar
• Lu, K. H. et al. Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recursive descent partition analysis. Clin. Cancer Res. 10, 3291–3300 (2004).
  Article CAS PubMed Google Scholar
• Hoffman, B. R. et al. Immunofluorometric quantitation and histochemical localisation of kallikrein 6 protein in ovarian cancer tissue: a new independent unfavourable prognostic biomarker. Br. J. Cancer 87, 763–771 (2002).
  Article CAS PubMed PubMed Central Google Scholar
• Kyriakopoulou, L. G. et al. Prognostic value of quantitatively assessed KLK7 expression in ovarian cancer. Clin. Biochem. 36, 135–143 (2003).
  Article CAS PubMed Google Scholar
• Shigemasa, K. et al. Human kallikrein 8 (hK8/TADG-14) expression is associated with an early clinical stage and favorable prognosis in ovarian cancer. Oncol. Rep. 11, 1153–1159 (2004).
  CAS PubMed Google Scholar
• Yousef, G. M. et al. Quantitative expression of the human kallikrein gene 9 (KLK9) in ovarian cancer: a new independent and favorable prognostic marker. Cancer Res. 61, 7811–7818 (2001).
  CAS PubMed Google Scholar
• Shigemasa, K., Gu, L., Tanimoto, H., O'Brien, T. J. & Ohama, K. Human kallikrein gene 11 (KLK11) mRNA overexpression is associated with poor prognosis in patients with epithelial ovarian cancer. Clin. Cancer Res. 10, 2766–2770 (2004).
  Article CAS PubMed Google Scholar
• Borgono, C. A. et al. Favorable prognostic value of tissue human kallikrein 11 (hK11) in patients with ovarian carcinoma. Int. J. Cancer 106, 605–610 (2003).
  Article CAS PubMed Google Scholar
• Scorilas, A. et al. Human kallikrein 13 protein in ovarian cancer cytosols: a new favorable prognostic marker. J. Clin. Oncol. 22, 678–685 (2004).
  Article CAS PubMed Google Scholar
• Yousef, G. M. et al. Steroid hormone regulation and prognostic value of the human kallikrein gene 14 in ovarian cancer. Am. J. Clin. Pathol. 119, 346–355 (2003).
  Article CAS PubMed Google Scholar
• Darson, M. F. et al. Human glandular kallikrein 2 (hK2) expression in prostatic intraepithelial neoplasia and adenocarcinoma: a novel prostate cancer marker. Urology 49, 857–862 (1997).
  Article CAS PubMed Google Scholar
• Nelson, P. S. et al. Molecular cloning and characterization of prostase, an androgen-regulated serine protease with prostate-restricted expression. Proc. Natl Acad. Sci. USA 96, 3114–3119 (1999). This is one of several papers to report the cloning of a novel kallikrein gene ( KLK4 ) in addition to KLK1, KLK2 and KLK3 , and one of the first indications of an extended human kallikrein gene family.
  Article CAS PubMed PubMed Central Google Scholar
• Day, C. H. et al. Characterization of KLK4 expression and detection of KLK4-specific antibody in prostate cancer patient sera. Oncogene 21, 7114–7120 (2002).
  Article CAS PubMed Google Scholar
• Obiezu, C. V. et al. Detection of human kallikrein 4 in healthy and cancerous prostatic tissues by immunofluorometry and immunohistochemistry. Clin. Chem. 48, 1232–1240 (2002).
  Article CAS PubMed Google Scholar
• Hooper, J. D. et al. Identification and characterization of klk14, a novel kallikrein serine protease gene located on human chromosome 19q13.4 and expressed in prostate and skeletal muscle. Genomics 73, 117–122 (2001).
  Article CAS PubMed Google Scholar
• Yousef, G. M. et al. Differential expression of the human kallikrein gene 14 (KLK14) in normal and cancerous prostatic tissues. Prostate 56, 287–292 (2003).
  Article CAS PubMed Google Scholar
• Yousef, G. M., Scorilas, A., Jung, K., Ashworth, L. K. & Diamandis, E. P. Molecular cloning of the human kallikrein 15 gene (KLK15). Up-regulation in prostate cancer. J. Biol. Chem. 276, 53–61 (2001).
  Article CAS PubMed Google Scholar
• Stephan, C. et al. Quantitative analysis of kallikrein 15 gene expression in prostate tissue. J. Urol. 169, 361–364 (2003).
  Article CAS PubMed Google Scholar